Crinetics Pharmaceuticals, Inc. announced an underwriting agreement on January 6, 2026, to sell 7.62 million shares of their common stock at $45.95 each, expecting to raise approximately $330.2 million, with a potential total of $379.8 million if the underwriters exercise their option to purchase more shares.